Read our newest eBook from Elif Alyanak, Haley Payne, MPH, and Mitchell Finkel on the evolving #vaccines ecosystem and key policy issues affecting vaccines manufacturers: https://lnkd.in/eSmyqvnZ
Avalere
Business Consulting and Services
Washington, DC 15,986 followers
Part of Avalere Health
About us
Avalere, part of Avalere Health , is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools, and custom analytics for leaders in healthcare business and policy. Avalere's experts span 200+ staff drawn from Fortune 500 healthcare companies, the federal government, and top consultancies and nonprofits. The firm offers advisory services on a wide range of healthcare business issues affecting healthcare companies. Avalere’s focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. Avalere sits within the Policy, Access, Value, and Evidence discipline of Avalere Health and collaborates with colleagues across the firm to offer actionable, thoughtful guidance to clients. Visit AvalereHealth.com to learn about our full Policy, Access, Value, and Evidence offering.
- Website
-
http://www.avalere.com
External link for Avalere
- Industry
- Business Consulting and Services
- Company size
- 201-500 employees
- Headquarters
- Washington, DC
- Type
- Public Company
- Specialties
- Health insurance and reform, Evidence-based medicine, Reimbursement and product commercialization, Health economics and outcome research, Healthcare networks, Post-acute and long-term care, Data analytics and modeling, and Financial Services
Locations
-
Primary
1201 New York Ave NW
Suite 1000
Washington, DC 20005, US
Employees at Avalere
Updates
-
💡 WEBINAR TODAY 💡 Join us at 1pm ET for an in-depth discussion on the regulatory and policy landscape of #RNA-based therapies. REGISTER HERE: https://lnkd.in/e7iAZQh3
-
Are you looking to influence #physician prescribing patterns, reduce #patient out-of-pocket costs, streamline product distribution, and boost profitability for your #pharmaceutical brand? Ify Jikeme Francis, John Neal, and Mina Alsaraf Allo explain how aligning brand strategies with payer goals allows #pharma companies to navigate the evolving market landscape and enhance patient outcomes: https://lnkd.in/eN8WB3W3 #PayerMarketing #PharmaStrategy #PatientAccess #HealthcareInnovation #Avalere #PharmaceuticalSuccess
-
📣 WEBINAR TOMORROW 📣 Join us at 1pm ET for a webinar on the #RNA-based therapy landscape, featuring #Avalere and external experts. REGISTER HERE: https://lnkd.in/e7iAZQh3 Mark Von Eisenburg, MS will be talking to Andrew Adams, Emily Mace, and Dr. Steven Nissen about the development and commercialization of RNA products, the future of innovative #biotechnologies, and #patient perspectives. See you tomorrow!
-
Join us this Thursday for a webinar on the key regulatory and policy questions on #RNA-based therapy. REGISTER HERE: https://lnkd.in/e7iAZQh3 Mark Von Eisenburg, MS will be moderating a panel with Andrew Adams, Emily Mace, and Dr. Steven Nissen on: ✔ How innovative #biotechnologies that leverage RNA are classified ✔ The current development landscape for RNA-based therapies ✔ The unique impact of the commercialization environment on RNA products ✔ Forward-looking perspectives on #patientaccess and policies influencing emerging therapies. ✔ Which diseases with unmet needs will benefit from Genetically Targeted Therapies
-
The policy and regulatory landscape that #healthplans operate in is changing rapidly. Clients trust Avalere to analyze the changing market to inform strategic decision making. We support end-to-end strategy—from ideation to implementation—business process optimization, and compliance reviews to help set plans up for success. Learn more about our work: https://lnkd.in/ePh_uy7d
-
On Tuesday the VP candidates debated the future of #drugpricing, #reproductiverights, the #ACA, and other top #healthcare issues. Read our latest #AvalereInsight for key takeaways: https://lnkd.in/eE6sUBbF
-
#CMS published the final IPAY 2027 Negotiation Guidance yesterday afternoon, #AvalereExperts like Milena Sullivan are digging into the detail: how the final guidance differs from the proposed guidance, how it differs from IPAY 2026 guidance, and what this means for manufacturers moving forward. Connect with us for customized insights:
#CMS released the final #IRA Negotiation Guidance for 2027. #AvalereExperts are reviewing the document for client considerations. Among the more notable changes is the fact that CMS is revising the initial offer process for selected drugs to use MFPs for therapeutic alternatives if these alternatives had been previously negotiated. This could have broad impacts on therapeutic dynamics. A few other initial highlights: •Revised timing of negotiation meetings and process for additional price exchanges •Refined definitions for the purposes of collecting manufacturer-specific data •Updated details on the patient-focused roundtable and townhall events to receive patient-focused and clinically-oriented information •Technical changes to ceiling price calculations •Finalized requirements for 2026 and 2027 MFP effectuation, including details on the data exchange, the voluntary payment facilitation functionality and 340B non-duplication •New requirement for manufacturers to have a process to mitigate material cash flow concerns for dispensing entities Reach out to learn more. #Avalere has already delivered 150+ IRA strategic projects to clients and has a deep bench of experts with experience with every aspect of the negotiation process - from early organizational readiness and pipeline risks, through evidence strategy and CMS engagement, all the way to MFP effectuation. Mike Ciarametaro Ashley Flint Taylor Schwartz Nicole Betor Maddi Davidson Jordan Banks, PhD, MPA #Medicare #drugpricing
-
#CMS recently released the 2025 #PartD and #MedicareAdvantage landscape files. #AvalereExperts are analyzing the data to assess trends in plan participation, beneficiary premiums, and benefit designs for the 2025 market. Connect with us to understand what this means for your organization: https://lnkd.in/eQic-Hmz #Medicare #healthplans
-
Join us Oct 10 for a robust discussion on the future of #RNA-based therapies: https://lnkd.in/e7iAZQh3 Avalere and external experts will: ✔ Clarify how innovative biotechnologies that leverage RNA are classified. ✔Explore the current development landscape for RNA-based therapies. ✔Address how the commercialization environment affects RNA products relative to other innovative biotechnologies. ✔Offer forward-looking perspectives on patient access and policies influencing emerging therapies. Moderated by #AvalereExpert Mark Von Eisenburg, MS and featuring Andrew Adams, Emily Mace, and Dr. Steven Nissen. #biotechnology #AvalereInAction